We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance (MUresv)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2011 by Marywood University.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01244360
First Posted: November 19, 2010
Last Update Posted: June 2, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Marywood University
  Purpose
The purpose of this study is to examine the effects of resveratrol on health and human performance. The study will evaluate cognitive function and several indicators of physical health before and after taking a resveratrol supplement or a placebo for three weeks.

Condition Intervention
Inflammation Dietary Supplement: resveratrol Other: Placebo Comparator: Sugar Pill

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance

Resource links provided by NLM:


Further study details as provided by Marywood University:

Primary Outcome Measures:
  • Vascular function [ Time Frame: 4 weeks, with option of additional 4 week treatment period ]
    vascular response to stress will be measured using flow mediated dilation and ultrasound.


Secondary Outcome Measures:
  • Body fat percentage [ Time Frame: 4 weeks, with optional additional 4 week treatment period ]
    Body fat percentage will be measured using a DEXA scan.

  • inflammation biomarkers [ Time Frame: 4 weeks, with optional additional 4 week treatment period ]
    Fasting blood draw

  • cognitive function [ Time Frame: 4 weeks, with optional additional 4 week treatment period ]
    cognitive function will be assessed using a validated computer based assessment tool


Enrollment: 44
Study Start Date: November 2010
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Sugar Pill
Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
Other: Placebo Comparator: Sugar Pill
Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
Active Comparator: Dietary Supplement: resveratrol
Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
Dietary Supplement: resveratrol
Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.

Detailed Description:

Measurements

  • blood laboratory parameters
  • cognitive assessment changes
  • body composition changes
  • vascular endothelial response
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • men and women between 45 and 75 years of age
  • Normal heart rate and Blood pressure
  • Ability to use personal computer interface
  • Successful completion of physical activity readiness questionnaire

Exclusion Criteria:

  • Cardiovascular disease, uncontrolled hypertension, lung disease
  • inability to tolerate exercise
  • have taken grape related supplement in past 12 months
  • current use of drugs or dietary supplements to enhance exercise performance
  • allergy to wine, grape juice or grape seed supplements
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01244360


Locations
United States, Pennsylvania
Marywood University
Scranton, Pennsylvania, United States, 18509
Sponsors and Collaborators
Marywood University
Investigators
Principal Investigator: James Smoliga, Ph.D. Marywood University
  More Information

Responsible Party: JAmes Smoliga, Ph.D., Marywood University
ClinicalTrials.gov Identifier: NCT01244360     History of Changes
Other Study ID Numbers: MU Smoliga Resveratrol
2RESMU194218 ( Other Identifier: Marywood University )
First Submitted: November 17, 2010
First Posted: November 19, 2010
Last Update Posted: June 2, 2011
Last Verified: June 2011

Keywords provided by Marywood University:
resveratrol
insulin
inflammation
cognition
metabolism

Additional relevant MeSH terms:
Resveratrol
Inflammation
Pathologic Processes
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents